Introduction
Indications for allogeneic hematopoietic stem cell transplantation (HCT) have changed in the past decade. The most common indication for HCT in 2013 was acute myeloid leukemia (AML), and currently nearly 50% of HCTs are being carried out for acute leukemia including AML and acute lymphoid leukemia (ALL). 1, 2 Furthermore, following the introduction of reduced intensity conditioning (RIC) regimens, individuals with co-morbidities and those 65 years of age and older are now eligible to undergo HCT. [3] [4] [5] The use of peripheral blood stem cells (PB) has largely replaced bone marrow (BM) as the main stem cell source for HCT in adults with hematologic malignancies. 1 However, limited data are available on the impact of the stem cell source (related or unrelated donor) in the setting of RIC HCT, [6] [7] [8] [9] [10] including our small previous European Group for Blood and Marrow Transplantation (EBMT) series. 9, 10 In 8 of 9 published comparative randomized studies, all participants received a myeloablative HCT, using different regimens depending on the underlying disease. 6 Only one randomized study by Anasetti et al. 7 included RIC regimens in the comparative analysis of BMT versus PBSCT for a variety of hematologic malignancies. Participants predominantly received a myeloablative HCT, with only 20% of the BMT group receiving RIC, and very few were performed for acute leukemia. A study recently published by the Center for International Blood and Marrow Transplant Research (CIBMTR) reported comparative analysis of BMT versus PBSCT after RIC regimen. 8 Similar to the report by Anasetti et al., 7 the study population included a variety of hematologic malignancies and the analysis included only 108 with AML patients in the BMT RIC group. Outcomes for unrelated donor allografting have improved over time. This is probably due to improved high-resolution HLA-typing and better matching, and the availability of intensive supportive care. 11, 12 Moreover, outcomes for unrelated donor HCT after RIC regimens appear comparable to those seen with sibling donor RIC HCT. 3, [13] [14] [15] Here we report on transplant outcomes after related or unrelated donor BMT (n=837) versus PBSCT (n=9011) in the setting of reduced intensity conditioning for the treatment of adults with acute leukemia using data reported to the ALWP of the EBMT from 2000 to 2012.
Methods

Study design and data collection
This was a retrospective multicenter registry analysis. Data were provided and approved for this study by the Acute Leukemia Working Party (ALWP) of the EBMT group registry. The EBMT is a non-profit, scientific society representing more than 600 transplant centers, mainly in Europe. The EBMT promotes all initiatives that aim to improve stem cell transplantation or cellular therapy, which includes registering all activities relating to stem cell transplants. Data are entered, managed, and maintained in a central database that includes all EBMT centers. There are no restrictions regarding centers that can report data except those legal requirements concerning patient consent, data confidentiality and accuracy. Quality control measures include several independent systems: confirmation of validity of the entered data by the reporting team, selective comparison of the survey data with MED-A data sets in the EBMT registry database, cross-checking with the national registries, and regular in-house and external data audits. Since 1990, patients have provided informed consent authorizing the use of their personal information for research purposes. Eligibility criteria for this analysis included adult patients (age >18 years) with acute leukemia receiving HLA-matched or mis-BMT or PBSCT after RIC regimen for acute leukemia haematologica | 2016; 101(2) 257 
Statistical analysis
The primary end points of the study were OS and LFS. Secondary end points included relapse incidence (RI), NRM, engraftment, incidence and severity of acute and chronic GvHD. The starting point for time-to-event analysis was date of transplantation. OS was defined as the time to death from any cause. Surviving patients were censored at time of last follow up. LFS was defined as survival without relapse or progression. Patients surviving in continuous CR were censored at the time of last follow up. RI was defined as time to onset of leukemia recurrence. NRM was the competing risk, and patients surviving in continuous complete remission were censored at last contact. NRM was defined as death without relapse/progression (relapse was the competing risk). The two groups were compared according to the stem cell sources (BM vs. PB) using the χ 2 test for qualitative variables, whereas the Mann-Whitney test was applied for continuous parameters. Univariate comparisons were made using the log rank test for OS, LFS, and the Gray test for RI, NRM and GvHD cumulative incidences. Multivariate analyses were performed using logistic regression for acute GvHD and Cox proportional hazards model for all other end points (variables tested are provided in Table 1 ). All factors known as potentially related to the outcome were included in the final model. First-order interactions between the main effect and the other variables were tested in multivariate models. All tests were two-sided. The type I error rate was fixed at 0.05 for determination of factors associated with time to event outcomes. Statistical analyses were performed with SPSS 22.0 (IBM Corp., Armonk, NY, USA) and R 3.1.1 software packages (R Development Core Team, Vienna, Austria).
Results
Patients', disease and transplant characteristics
Details of patients', disease and transplant characteristics are summarized in Table 1. A total of 9848 patients with AL were included in the study: 837 patients received BM and 9011 PB transplants performed between 2000 and 2012; 8777 (89.1%) patients had AML (BM=702, PB=8075) and 1071 (10.9%) ALL (BM=135, PB=936). PBSCT recipients were older with a median age of 57 years (range 18-77) in comparison to 54 years (range 18-77) for the BM group (P<0.0001). Median follow up of surviving patients in the BM group was 29 (IQR, 12-56) months, while that of the PB group was 27 (IQR, 11-54) months (P=0.27). Significantly higher numbers of patients had Karnofsky Performance Status (KPS) score less than 90% (37 vs. 31%; P=0.006) in the BM group. There were more patients with advanced disease in PB compared to the BM group (26 vs. 22%; P=0.002). There were no statistically significant differences in cytogenetic risk categories in AML or ALL groups between patients receiving BM or PB transplantations. The proportion of CMV seropositive recipients and donors were comparable in the BM and PB groups [69% vs. 67% (P=0.26) and 54% vs. 53% (P=0.69), respectively].
Details of transplant characteristics and conditioning regimen are summarized in Table 1 . The majority of patients received chemotherapy-based RIC regimens (BM=75%, PB=70%; P=0.002). Among the BM recipients, 388 (46%) received a graft from HLA-identical sibling donor, 220 (26%) matched unrelated donor (MUD) (10/10), 107 (13%) mismatched unrelated donor (MM-URD) (9/10), and 122 (15%) received mismatched-related donor HCT; corresponding numbers in the PB cohort were 4751 (53%), 2894 (32%), 950 (10%), and 416 (5%), respectively. The percentage of patients receiving in vivo T-cell depletion was higher in the PB group (61% vs. 48% in BM; excluded from the analysis. The choice of conditioning, graft source and GvHD prophylaxis was dependent on the protocols of the individual centers and the strategies adopted for transplantation.
Engraftment and graft-versus-host disease
Median time to neutrophil recovery (PMN ≥0.5x10 9 /L) was 20 days and 16 days after BM and PB HCT, respectively (P<0.0001). The corresponding day 60 probability of neutrophil recovery (PMN ≥0.5x10 9 /L at day 60) was 88% (95%CI: 86-90) after BM versus 95% (95%CI: 95-96) in the PB group (P<0.0001).
The rates of day 100 grade II-IV acute GvHD were 24% versus 19% (P=0.005) and 10% versus 6% (P=0.003) for grade III-IV GvHD in PB compared with BM transplant recipients.
In multivariate analysis, the factors associated with increased risk of grade II-IV acute GvHD were PB versus BM (OR 1.31; 95%CI: 1.07-1.60; P=0.008; Figure 1 ). The severity of chronic GvHD was graded as extensive in 1287 (16.6%) of PBSCT recipients compared with 69 (9.3%) in the BMT group (P<0.0001). Similarly, the GvHD-related mortality was higher after PBSCT compared to BMT (13% vs. 7.4%; P=0.001).
In multivariate analysis, chronic GvHD was significantly higher after PB grafts (HR 1.38; 95%CI: 1.17-1.60; P<0.0001) ( Figure 1) .
A B C D E
Non-relapse mortality
In multivariate analysis, RI was significantly lower after PB grafts (HR 0.78, 95%CI: 0.69-0.88; P=0.0001) ( Table 2 ). 
Leukemia-free survival
Two-year LFS was higher after PB (44%, 95%CI: 43-45) compared with BM transplants (39%, 95%CI: 35-42) (P=0.009) ( Table 3 and Figure 1) .
In multivariate analysis, the only factor associated with superior LFS was the use of PB grafts (HR 0.88, 95%CI: 0.79-0.97; P=0.01) ( Table 2) .
Factors associated with inferior LFS independent of graft source were diagnosis of ALL versus AML (HR 1. 
Overall survival
Two-year OS was higher after PB grafts (50%, 95%CI: 49-52) compared with BM transplants (47%, 95%CI: 44-51) (P=0.05) ( Table 3 and Figure 1 ). In multivariate analysis, factors associated with superior OS were PB grafts (HR 0.90, 95%CI: 0.81-1.00; P=0.05) ( Table 2 ) and in vivo T-cell depletion (HR 0.93, 95%CI: 0.87-1.00; P=0.04).
Factors associated with inferior OS independent of graft source included a diagnosis of ALL versus AML (HR 1.42 
Impact of graft source on other variables
The primary purpose of our analysis was to explore outcome differences between BM and PB transplantation in patients with acute leukemia after RIC regimens. The effect of stem cell source (BM vs. PB) on survival was independent of disease (interaction test P=0. 22) . There was no significant interaction between the graft source and disease status at transplant (interaction test P=0.57). Results were similar among HLA-mismatched pairs and recipients with active disease, although this study was not designed to detect potential differences within these subsets.
Discussion
This large, multicenter, registry study shows that the use of PB grafts after RIC gives superior outcome in patients with acute leukemia. Moreover, PBSCT recipients had a lower risk of relapse, most probably due to a stronger graft-versus-leukemia (GvL) effect not just in patients in CR, but, more importantly, in patients with active disease pre-HCT. This finding is of major clinical significance as an increasing number of patients are undergoing RIC HCT for acute leukemia, a significant number of whom receive BM grafts; 1 indeed, 8.5% (n=837) of 9848 patients transplanted from 2000 to 2012 at centers reporting to the EBMT received BM grafts. However, the increased risk of chronic GvHD observed in our series after PB grafts is alarming, and long-term follow up is awaited to clarify if excess risk of chronic GvHD among RIC PBSCT recipients translates into continued GvL effect or increased late morbidity and mortality. 19 We investigated patient, disease, and transplantation factors affecting survival, LFS, relapse, NRM and GvHD in a well-characterized population of nearly 10,000 adult acute leukemia patients receiving either BMT or PBSCT.
Overall, nearly 50% of patients (Figure 1 ) transplanted after RIC HCT survived beyond two years, with higher survival for AML compared to ALL. Notably, the low-dose TBI-based regimen had inferior outcome (for both patients in CR1 and active diseases) compared to chemotherapybased RIC regimens. Results were similar among related or unrelated donor groups.
Patients receiving in vivo T-cell depletion (either ATG or alemtuzumab) had a significantly lower risk of chronic GvHD and higher OS despite their higher relapse rate, which was offset by lower NRM. Anti-thymocyte globulin or alemtuzumab with standard GvHD prophylaxis (which has been shown to be effective in lowering GvHD rates as well as its severity) was used for 48% of BM and 61% of PB transplantations in our series. This study was not designed to analyze separately patients receiving lowdose ATG/alemtuzumab, which is commonly used today; however, previous studies have shown that low-dose ATG/alemtuzumab reduced the risk of chronic GvHD and NRM without compromising the GvL effect. [20] [21] [22] [23] [24] [25] Previous smaller studies demonstrated the non-inferiority of RIC PBSCT compared to RIC BMT for patients with acute leukemia. [7] [8] [9] [10] Our results differ from the findings in published studies comparing RIC outcomes with BM with PB grafts. This discrepancy may be due to differences in the study populations. Firstly, the improved survival, decreased relapse risk and higher rates of grade II to IV acute GvHD (also grade III-IV) after transplants with PB compared with BM grafts are in contrast to previous reports. 6, 8, 26 The survival rates in the BM and PB groups in our study are comparable to a study from the CIBMTR by Eapen et al., 8 reporting a 3%-5% difference in OS and LFS between the two groups, which was not statistically significant. In our analysis, results were statistically significant, and this may reflect the difference in power between the two studies. Secondly, the cumulative incidence of engraftment and the risk of chronic GvHD were higher after PBSCT compared with BMT, in keeping with other reports. 6, 7, 27, 28 Chronic GvHD can impair quality of life and is associated with significant morbidity and mortality among HCT recipients. However, the costs involved, the economic burden and the use of resources to manage long-term complications associated with cGvHD have not been well described. Studies of transplantation costs are complex and difficult to conduct because of the wide variation in transplant methods, conditioning approaches, GvHD prophylaxis regimens and supportive care practices. More research is needed to better understand the costs of cGvHD to patients, centers and the health care system, and to determine whether the lower incidence and severity of cGvHD with BM grafts leads to long-term savings of resources compared to PB grafts. Also, trials aimed at better GvHD prophylaxis that is either drug-mediated or through graft manipulation are needed to reduce chronic GvHD rates after RIC PBSCT.
We acknowledge that there are differences in patients', disease, and transplantation characteristics between those who received BMT and PBSCT. We have addressed this by performing a carefully controlled well-adjusted analysis that considered patients', disease, and transplantation characteristics as well as any transplantation center effects in this multicenter registry analysis. In addition, there may be unmeasured and unknown factors that have not been considered, which is an inherent limitation of this type of analysis. However, we believe that the results of this analysis are very important in the absence of available prospective data.
Only through the conduct of well-designed clinical trials will we be able to understand and appreciate the complexities of stem cell source choices and their outcome after RIC HCT. Unfortunately, there are no ongoing trials to compare outcomes after BMT with that after PBSCT following an RIC regimen for acute leukemia. Therefore, in the absence of any prospect of such comparative studies, our data support the use of PB (related or unrelated donor) grafts after RIC for adult patients with acute leukemia in remission or with advanced disease.
